<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg"/></p>
<p>佩维福斯科维钠是一种潜在的首创衣壳组装调节剂，正在开发用于治疗慢性乙型肝炎病毒（HBV）。图片来源：Jarun Ontakrai / Shutterstock.com。</p>
<p>Aligos Therapeutics 与厦门安默拓生物科技签署了独家许可协议，旨在为大中华区的慢性乙型肝炎病毒（HBV）感染开发和商业化佩维福斯科维钠。</p>
<p>该地区包括香港、澳门、中国大陆和台湾。合作的重点是满足该地区超过 9000 万受 HBV 影响人群的需求。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>乙型肝炎病毒感染 - 全球药物预测和市场分析...</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>根据协议，Aligos 将获得 2500 万美元的前期里程碑付款。</p>
<p>该公司仍有资格获得高达 4.2 亿美元的额外临床、监管和销售里程碑付款，以及在安默拓许可区域的净销售额中分级的高个位数特许权使用费。</p>
<p>Aligos 保留在大中华区以外的佩维福斯科维钠开发和商业化活动的所有权利，特别是在欧洲、日本、韩国和美国，并将在大中华区进行临床试验。</p>
<p>根据现有的运营计划，该公司预计此交易将延续其当前的现金、现金等价物和投资至 2026 年第四季度。</p>
<p>佩维福斯科维钠是一种潜在的首创衣壳组装调节剂（CAM-E），正在开发用于治疗慢性 HBV。</p>
<p>目前正在进行 II 期 B-SUPREME 研究，比较其与替诺福韦二吡呋酯（TDF）的疗效。第二次中期分析预计将在 2026 年下半年进行，最终的顶线数据预计在 2027 年发布。</p>
<p>厦门安默拓生物科技董事长兼首席执行官孙力表示：“Aligos 处于 HBV 创新的前沿，我们很高兴能与这个杰出的团队深化合作。我们相信佩维福斯科维钠有潜力改变慢性 HBV 的抑制，我们为能够在大中华区许可这一重要项目感到自豪。</p>
<p>“随着我们继续构建我们的产品组合，包括与 Aligos 合作的 ASO 和已批准的 PEGBING 疗法，我们期待探索能够为该地区患者带来实质性益处的组合方案。”</p>
<p>协议的签署预计将在 30 天内完成，需经厦门安默拓生物科技股东批准。</p>

ALGS

美国制药 ETF - iShares

基因改革 ETF - ARK

<p>Aligos Therapeutics 已与厦门安默拓生物科技签署独家许可协议，以开发和商业化用于慢性 HBV 感染的佩维福斯可维钠，适用于大中华区，包括香港、澳门、 mainland China 和台湾。Aligos 将获得 2500 万美元的预付款，并有可能获得高达 4.2 亿美元的额外里程碑付款。该药物目前正在进行第二阶段临床试验，预计最终数据将在 2027 年公布。该协议需经股东批准，预计将在 30 天内完成</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg"/></p>
<p>Pevifoscorvir sodium is a potential first-in-class capsid assembly modulator being developed to treat chronic HBV. Credit: Jarun Ontakrai / Shutterstock.com.</p>
<div class="lb-trans"><p>佩维福斯科维钠是一种潜在的首创衣壳组装调节剂，正在开发用于治疗慢性乙型肝炎病毒（HBV）。图片来源：Jarun Ontakrai / Shutterstock.com。</p>
</div><p>Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.</p>
<div class="lb-trans"><p>Aligos Therapeutics 与厦门安默拓生物科技签署了独家许可协议，旨在为大中华区的慢性乙型肝炎病毒（HBV）感染开发和商业化佩维福斯科维钠。</p>
</div><p>This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by HBV in this region.</p>
<div class="lb-trans"><p>该地区包括香港、澳门、中国大陆和台湾。合作的重点是满足该地区超过 9000 万受 HBV 影响人群的需求。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Hepatitis B Virus Infection - Global Drug Forecast and Market Analy...</h4>
<div class="lb-trans"><h4>乙型肝炎病毒感染 - 全球药物预测和市场分析...</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Under the agreement, Aligos will receive an upfront milestone payment of $25m.</p>
<div class="lb-trans"><p>根据协议，Aligos 将获得 2500 万美元的前期里程碑付款。</p>
</div><p>The company remains eligible to receive up to $420m in additional clinical, regulatory, and sales milestones, along with tiered, high single-digit royalties on net sales in Amoytop’s licensed areas.</p>
<div class="lb-trans"><p>该公司仍有资格获得高达 4.2 亿美元的额外临床、监管和销售里程碑付款，以及在安默拓许可区域的净销售额中分级的高个位数特许权使用费。</p>
</div><p>Aligos retains all rights for the development and commercialisation activities of pevifoscorvir sodium outside of Greater China, specifically in Europe, Japan, South Korea, and the US, and will conduct clinical trials in Greater China.</p>
<div class="lb-trans"><p>Aligos 保留在大中华区以外的佩维福斯科维钠开发和商业化活动的所有权利，特别是在欧洲、日本、韩国和美国，并将在大中华区进行临床试验。</p>
</div><p>The company expects this deal to extend its current cash, cash equivalents, and investments into the fourth quarter of 2026, based on its existing operating plan.</p>
<div class="lb-trans"><p>根据现有的运营计划，该公司预计此交易将延续其当前的现金、现金等价物和投资至 2026 年第四季度。</p>
</div><p>Pevifoscorvir sodium is a potential first-in-class capsid assembly modulator (CAM-E) being developed to treat chronic HBV.</p>
<div class="lb-trans"><p>佩维福斯科维钠是一种潜在的首创衣壳组装调节剂（CAM-E），正在开发用于治疗慢性 HBV。</p>
</div><p>It is being assessed in the Phase II B-SUPREME study at present, which compares it to tenofovir disoproxil fumarate (TDF). The second interim analysis is expected during the second half of 2026, with final top line data anticipated in 2027.</p>
<div class="lb-trans"><p>目前正在进行 II 期 B-SUPREME 研究，比较其与替诺福韦二吡呋酯（TDF）的疗效。第二次中期分析预计将在 2026 年下半年进行，最终的顶线数据预计在 2027 年发布。</p>
</div><p>Xiamen Amoytop Biotech chairman and CEO Sun Li said: “Aligos is at the forefront of HBV innovation, and we are pleased to deepen our partnership with this outstanding team. We believe pevifoscorvir sodium has the potential to transform chronic HBV suppression, and we are proud to license this important programme for Greater China.</p>
<div class="lb-trans"><p>厦门安默拓生物科技董事长兼首席执行官孙力表示：“Aligos 处于 HBV 创新的前沿，我们很高兴能与这个杰出的团队深化合作。我们相信佩维福斯科维钠有潜力改变慢性 HBV 的抑制，我们为能够在大中华区许可这一重要项目感到自豪。</p>
</div><p>“As we continue to build our portfolio, including the Aligos-partnered ASO and approved PEGBING therapy, we look forward to exploring combination approaches that deliver meaningful benefits to patients across the region.”</p>
<div class="lb-trans"><p>“随着我们继续构建我们的产品组合，包括与 Aligos 合作的 ASO 和已批准的 PEGBING 疗法，我们期待探索能够为该地区患者带来实质性益处的组合方案。”</p>
</div><p>Closing of the agreement is expected within 30 days, subject to Xiamen Amoytop Biotech shareholder approval.</p>
<div class="lb-trans"><p>协议的签署预计将在 30 天内完成，需经厦门安默拓生物科技股东批准。</p>
</div>

Aligos 与厦门艾美拓签署 HBV 治疗协议